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Physiological changes during gestation are important to be aware of in measurement and interpretation of thyroid function
tests in women with autoimmune thyroid diseases. Thyroid autoimmune activity is decreasing in pregnancy. Measurement of
serum TSH is the ﬁrst-line screening variable for thyroid dysfunction also in pregnancy. However, using serum TSH for control
of treatment of maternal thyroid autoimmunity infers a risk for compromised foetal development. Peripheral thyroid hormone
values are highly diﬀerent among laboratories, and there is a need for laboratory-speciﬁc gestational age-related reference ranges.
Equallyimportant,theintraindividualvariabilityofthethyroidhormonemeasurementsismuchnarrowerthantheinterindividual
variation (reﬂecting the reference interval). The best laboratory assessmentof thyroid function is a free thyroid hormoneestimate
combined with TSH. Measurement of antithyroperoxidase and/or TSH receptor antibodies adds to the diﬀerential diagnosis of
autoimmuneand nonautoimmunethyroid diseases.
1.Introduction
Diagnosing maternal thyroid dysfunction during all stages
of pregnancy is very important for the outcome for both
mother and foetus [1, 2]. Women with hypothyroidism
treated insuﬃciently with levothyroxine (high serum con-
centration of thyrotropin (TSH) or serum free thyroxine
(T4) in the low normal range) deliver babies with signiﬁ-
cantly lower IQ and/or other inhibited neuropsychological
development [3, 4]. Such oﬀspring outcome has even been
demonstrated in women with a serum concentration of T4
in the low normal range during pregnancy [5].
Prevalence of autoimmune thyroid disease (AITD) is
high in women of reproductive age, whether or not they
are pregnant [6]. AITD not only aﬀects fertility [6], but
may also lead to a decreased thyroid reserve with decreased
availability of thyroxine. This is particularly important in
the ﬁrst half of pregnancy, in which the foetal development
depends on the delivery of thyroxine from the mother [7, 8].
Althoughautoimmunethyrotoxicosis,Graves’disease, israre
in pregnant women, transfer of TSH receptor antibodies,
which can be either stimulating or blocking, may give rise
to foetal and neonatal thyrotoxicosis or hypothyroidism,
respectively [9, 10].
As a natural consequence of the importance of thyroid
hormones forfoetal brain developmentmuch focushas been
given to diagnosing both overt and subclinical (or mild)
thyroid dysfunction as early as possible in pregnant women,
recently resulting in international consensus guidelines
[10]. Although the guidelines do not recommend universal
screening of all pregnant women, most specialised clinical
caretakers would attempt at including as many women
as possible in a case ﬁnding programme. Women with
autoimmune thyroid diseases or a family history of such
belong to the risk groups [10].
Apart from general global problems in accomplish-
ing this type of care due to ﬁnancial and/or infrastructure
restrictions, there are also many other reasons why these2 Journal of Thyroid Research
eﬀorts have limited success. One of them is associated
with the biochemical measurements of thyroid function
undergoing many complicated changes during pregnancy,
and the corresponding issue of educating these important
matters to the physicians who are caretakers of pregnant
women. The question of whether precise detection and
adequate treatment of thyroid insuﬃciency in pregnancy
are feasible is still unanswered but recent progress and
better insights into physiological changes, trimester-speciﬁc
reference ranges, and intra- versus interindividual variability
on the assessment of thyroid function in the single pregnant
woman should give a better background for the future
[11–13]. The present paper will focus on the choice of
tests for assessment of biochemical thyroid function in
pregnant women with AITD, together with their strengths
andlimitations.Informationfromtworecentguidelineshave
been used in part as reference [10, 14]a sw e l la st h ew e b -




Normalpregnancy entails complicatedand substantial chan-
ges in thyroid function [15]. The circulating thyroid hor-
monebindingglobulin(TBG)increases duetoanoestrogen-
induced increase in its production and at the same time the
serum iodine decreases, the synthesis of thyroid hormones
is increased, there are changes in the deiodinase activity,
and, toward the end of the ﬁrst trimester, when chorionic
gonadotropin (HCG) levels are the highest, a signiﬁcant
fraction of the thyroid-stimulating activity is from HCG.
Furthermore, thyroid autoimmune activity—reﬂected by
thyroid autoantibody concentrations in serum—is usually
decreasing due to a general immune suppressive action
from the pregnancy, and ﬁnally plasma volume expands
by approximately 50%, resulting in, for example, a lower
serumalbumin concentration.Serumconcentrationsoftotal
T4 and T3 increase due to the increase of TBG. Serum
concentrations of free thyroid hormones and TSH should
physiologically be within normal limits, except in the short
period of time when TSH may become suppressed due to
the HCG eﬀect (gestational hyperthyroidism). But it must
be emphasised that normal reference ranges from a non-
pregnant population are not to be considered “normal” in
pregnancy. All the above-mentioned physiological changes,
including the high TBG concentration, inﬂuence the lab-
oratory measurements even of the free thyroid hormones.
There istherefore ahugerisk offalse interpretationofthyroid
function tests in pregnancy [16].
3.Biochemical Diagnosis of
Thyroid DysfunctioninPregnancy
3.1. Measurement of Serum TSH. The most sensitive method
for screening for thyroid dysfunction in a healthy, non-
pregnant population is the measurement of TSH serum
concentration due to the log-linear relationship between
TSH and free T4: even small changes in T4 concentrations
will provoke very large changes in serum TSH. However,
in pregnant women thyroid and pituitary functions are
not stable, and, therefore, measuring TSH is not suﬃcient
and often inappropriate for the assessment of thyroid
function during gestation. If serum TSH measurement is
used alone, the mother is likely to be insuﬃciently treated
with levothyroxine for hypothyroidism or overtreated with
antithyroid drugs for thyrotoxicosis, both of which resulting
in maternal hypothyroidism, which in turn seriously aﬀects
the foetal brain development.
A typical example of such biochemical misdiagnosis
during followup of antithyroid drug-treated Graves’ disease
is demonstrated in one of the cases from our tertiary referral
department [17]. A 32-year-old 24-weeks pregnant woman
wasreferred from alocalhospital duetotheﬁnding ofa large
foetal goitre by routine scan. It was her second pregnancy,
and she had been treated with antithyroid drugs for Graves’
diseasefor9years.Thisincludedtreatmentduringaprevious
pregnancy 5 years before, which resulted in a male baby
with severely reduced cerebral capacity. Upon referral she
was treated with 20mg thiamazole daily. She had at the
local hospital been considered suﬃciently euthyroid based
on a normal TSH of 2.9 mU/L (population-based reference
range 0.4–4.0mU/L), total T4 97nmol/L (60–140nmol/L),
and free T4 7.8pmol/L (7–20pmol/L). She had a high level
of TSH receptor antibodies at 24U/L (<1.5U/L). A more
elaborate foetal ultrasound showed a male foetus with poly-
hydramnios and an enlarged thyroid gland with measures of
1.4 × 3.5 × 3.5cm, which was predominantly intrathoracic.
Cord blood TSH was highly elevated at 34.5mU/L, and free
T4 was reduced to 13.8pmol/L. The misdiagnosis of the
thyroid function had been based primarily on the normal
maternal levels particularly of TSH, which were, however,
reﬂecting a delayed pituitary reaction to the slightly lowered
free thyroid hormone levels. It is mandatory for doctors
taking care of pregnant women with thyroid diseases to have
a thoroughknowledgeofthe evolutionofthenormal thyroid
function during pregnancy as well as during treatment of
thyroid dysfunction in order to avoid such unfortunate and
unnecessary cases [17].
3.2. Measurement of Total or Free Thyroid Hormones. Mea-
surement of the peripheral thyroid hormones themselves is
complicatedbyanumberofproblems,themostimportantof
which is the relationship to the gestation-induced elevation
oftheserumconcentrationofTBG.Sincemostlyimmunoas-
saysare used, biasedvaluescan derivefromthyroid hormone
antibodies in a woman with autoimmune thyroid disease,
or heterophilic antibodies interfering in either the assays for
TSH or thyroid hormones [18]. The elevated total hormone
concentrations during gestation can display diverse reactions
in the free thyroid hormone assays, either performing by
giving a correct value or in most situations resulting in
either over- or undercorrection. Consequently, results of
free thyroid hormone measurements may very likely be
either over- or underestimated leading to wrong diagnosis. A
more reliable free thyroid hormone estimate is provided by
measurement of total hormone concentrations (T3 and T4)Journal of Thyroid Research 3
and correction for the increased binding proteins by either
direct measurement of TBG (to provide T4/TBG or T3/TBG
ratios) or a T3 or T4 uptake test. The latter can be calculated
into free thyroid hormone indices, but as discussed in a very
recent paper [19] these indices may also be incorrect during
late pregnancy, probably due to insuﬃcient correction of
such extreme elevation of binding proteins, for which the
methods are not designed. A qualitative or semiquantitative
assessment of the total hormone concentrations and binding
proteinmeasurementseparatelymay,however,beuseful,and
more so than the single free thyroid hormone results. It is
important tonotethattheavailabilityofthesemeasurements
depends on the local clinical biochemical laboratory.
From a clinical biochemical point of view total hormone
measurements and creation of free thyroid hormone mea-
surements are strictly the most reliable tests with the highest
precision and accuracy. Very recently free thyroid hormones
have been measured by equilibrium dialysis isotope dilution
tandemmassspectrometry, which providesaccurate,precise,
fast, and simple measurements [20–24]. Such methods are,
however, not generally available yet, and most laboratories
still use immunoassays. In a recent paper, 3 immunoassays
were compared with tandemmass spectrometry, and 2 of the
3 assays performed similarly to tandem mass spectrometry
in late pregnancy, even when all 3 assays were dependant on
binding proteins [19]. Thus, overall, the results of thyroid
function testing during pregnancy are still puzzling and




Another problem in thyroid function tests is the population-
based reference ranges, because they depend not only on the
composition of the populationand the iodine intake butalso
highly on the laboratory methods used. Therefore, there is
a strong need of laboratory-dependent reference ranges, in
order not to rely only on the reference range provided by the
assay manufacturer. Because the progression of pregnancy
and foetal, neonatal, and child health are dependent on
adequate thyroid hormone supplementation throughout
pregnancy, trimester-speciﬁc reference intervals for thyroid
functions can be crucial for both maternal and foetal health.
The physiologic changes associated with pregnancy require
an increased availability of thyroid hormones by 40% to
100% to meet the needs of mother and foetus. Trimester-
speciﬁcpopulation-basedreferencerangesinordertocorrect
for the physiological changes with increasing total hormone
concentration and de- or increasing free hormones and
suppressed TSH have been published from many sources in
recent years [13,24–37].Thisapproachwill reducetheglobal
variability of thyroid hormone assessment by approximately
6–18% [27], but it is important to emphasize that, for
this to occur, the use of laboratory and population-speciﬁc
ranges is crucial, since measurements by diﬀerent methods
in diﬀerent populations do provide very diﬀerent ranges
(examples shown in Table 1). The table is not extensive but
just examples of the most recent publications are shown.
When producing trimester-speciﬁc reference ranges it is
important that seemingly normal women with thyroperox-




Another, probably even more important, problem compli-
cating the use of population-based reference ranges also in
pregnant women is that each individual has its own genetic
setpoint, as it has been shown by Feldt-Rasmussen et al.
[12] and recently by Andersen et al. [38] in a nonpregnant
population. In the initial studies when the methods for
measurement of thyroid function had a lower sensitivity and
higher imprecision the intraindividual coeﬃcient of varia-
tion (CV%) was between 6 and 17% [12], also conﬁrmed in
a recentpublicationusing moremodernmethods[39],while
the interindividual CV% was 11 to 25%. A more relevant
way of evaluating this is through an individuality assessment
which was in these studies below 0.5, indicating that the
thyroid function cannot be meaningfully assessed by the
populations-based reference ranges [12, 13, 38–40]. Boas
et al. [13] found a similar magnitude of variability in healthy
pregnant women with an interindividual variability of 13–
20% for both total and free T3 and T4, independent of
gestational week, and an intraindividual variability of the
same variables of 8–10%.
It is therefore very possible that also during pregnancy
changes within the same woman are more important than
the speciﬁc single measurement in relation to a speciﬁc
reference range [13, 41]. In this case it applies also when
using gestation-speciﬁc reference ranges, although the latter
have to be considered also. This will result in a reduction of
the total variability of the thyroid hormone function tests.
The mentioned gestation-speciﬁc reference ranges should,
however, be assessed in a given population with the given
assays used in the laboratory and should not solely be
based on information from the kit manufacturer, from the
literature, or from another neighbouring laboratory, even if
this laboratory uses the same assay.
6.Thyroid Autoantibodies
The measurement of thyroid autoantibodies in pregnant
women is mainly useful to substantiate the probability of
thyroid dysfunction in biochemically unclearcases, to ensure
ac o r r e c td i ﬀerential diagnosis in case of maternal dysfunc-
tion, to predict the risk for development or deterioration
of maternal thyroid dysfunction, and in few situations to
predict for intrauterine and/or neonatal dysfunction [10,
14, 15]. Aﬀection of the foetus and neonate is probably
exclusively related to the presence and placental transfer of
TSH receptor antibodies, which can also predict maternal
hyperthyroidism in 60–70% of cases. When it comes to
hypothyroidism the NHANESIII study found almost similar
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Table 2:Whattodoinclinicalpracticeconcerningthyroidfunction
tests in pregnancy, when diagnosing hypo- or hyperthyroidism,
respectively?
(i) Hypothyroidism:
(a) Serum TSH, evaluation respecting the gestation-induced
suppression
(b) Measurement of antithyroperoxidase antibodies
(c) Sometimes measurement of TSH receptor antibodies and/or
thyroglobulin antibodies
(d) Free T4 estimate
(1) “Direct measurement” with diﬃculty of interpretation
(2) MeasurementoftotalT4 andT3 uptake test—morereliable
(3) Measurement of total T4 and correcting by 50% increase
for pregnancy/TBG eﬀect
(ii) Hyperthyroidism:
(a) Serum TSH, evaluation respecting the gestation-induced
suppression
(b) Measurement of TSH receptor antibodies
(c) Free T4 estimate/free T3 estimate
(1) “Direct measurement” with diﬃculty of interpretation
(2) Measurement of total T4/T3 and T3 uptake test—more
reliable
(3) Measurement of total T4/T3 and correcting the nonpreg-
nant reference range by 50% increase for pregnancy/TBG
eﬀect
Adapted from: [10].
autoantibodies in this normal population. However, only
antithyroperoxidase antibodies were signiﬁcantly associated
with hypothyroidism (as well as with hyperthyroidism),
whereas antithyroglobulin antibodies were not [42].
7.Conclusions
In conclusion, in clinical practice doctors should use all
available thyroid function tests relevant for the diagnosis
o ft h eA I T Di nq u e s t i o n( s e eTable 2) to avoid the risk of
false interpretations and the resulting potential irreversible
damage to the foetal brain. Both total and free thyroid
hormonesareliabletofalse resultsduringpregnancy,andthe
biochemicalpanelofmeasurements performed when thereis
a suspicion of hypo- and hyperthyroidism should therefore
be supplemented with antithyroperoxidase antibodies, in
case of suspected hypothyroidism [42], and TSH receptor
antibodies, in case of suspected hypo- or hyperthyroidism,
respectively [43]. TSH is insuﬃcient as sole and ﬁrst-line
diagnostic variable due to the thyroid-pituitary instability
duringpregnancy andtosuppressionduringthehighpeakof
HCG at the end of the ﬁrst trimester. Only women without
thyroperoxidase antibodies should be included when pro-
ducing trimester speciﬁc reference ranges. The ﬁnding of
low intraindividual variation of the thyroid hormones in
serum would speak in favour of using the woman’s own
evolution of the thyroid hormones when diagnosing hypo-
orhyperfunction. Sincethisisforobviousreasonsnot always
possible, the use of trimester-speciﬁc references may at least
serve to reduce the variability and improve diagnostics.
Access to a broad spectrum of thyroid function tests
must be considered a prerequisite for taking proper care
of pregnant women with AITD. Due to the high TBG
concentration, the best laboratory assessment of thyroid
function also in AITD is a free thyroid hormone estimate—
in hypothyroidism a free T4 estimate combined with TSH
and in hyperthyroidism free T4 and T3 estimates combined
with TSH. These free thyroid hormone measurements do
not always correct completely for the binding protein abnor-
malities. Thus, if in doubt, samples should be measured in
another laboratory with diﬀerent platforms for free thyroid
hormone measurements or combined with total hormone
measurement and a T3 uptake test. Measurement of antithy-
roperoxidase, antithyroglobulin, and/or TSH receptor anti-
bodies will add to the diﬀerential diagnosis between AITD
and nonautoimmune thyroid disease. Thus, presence ofTPO
antibodies very often predicts the risk of hypothyroidism,
and,inpregnantwomenwithlowTSH,hyperthyroidism will
be predicted by TSH receptor antibodies in 60–70%.
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